Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | METAP1 | P53582 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | ADH1B | P00325 | 1/20 | 0.39 |
| ▸ | ADH1C | P00326 | 1/20 | 0.39 |
| ▸ | ADH1A | P07327 | 1/20 | 0.39 |
| ▸ | ADH4 | P08319 | 1/20 | 0.39 |
| ▸ | ADH7 | P40394 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL60593 | 1.00 | — | — | |
| SCHEMBL3027711 | 1.00 | CYP1A2 (0.48) | CYP1A2SIGMAR1HPGDMETAP1EPHX1 | |
| SCHEMBL8176343 | 1.00 | CYP1A2 (0.48) | CYP1A2SIGMAR1HPGDMETAP1EPHX1 | |
| SCHEMBL866084 | 1.00 | CYP1A2 (0.48) | CYP1A2SIGMAR1HPGDMETAP1EPHX1 | |
| SCHEMBL866633 | 1.00 | CYP1A2 (0.48) | CYP1A2SIGMAR1HPGDMETAP1EPHX1 | |
| SCHEMBL178170 | 1.00 | CYP1A2 (0.48) | CYP1A2SIGMAR1HPGDMETAP1EPHX1 | |
| SCHEMBL21831394 | 1.00 | CYP1A2 (0.48) | CYP1A2SIGMAR1HPGDMETAP1EPHX1 | |
| SCHEMBL21114318 | 1.00 | CYP1A2 (0.48) | CYP1A2SIGMAR1HPGDMETAP1EPHX1 | |
| SCHEMBL21831579 | 1.00 | CYP1A2 (0.48) | CYP1A2SIGMAR1HPGDMETAP1EPHX1 | |
| SCHEMBL22434 | 0.97 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3597670-B1 | WATER-SOLUBLE COMPOSITION, PRODUCTION METHOD FOR CURED PRODUCT THEREOF, AND CURED PRODUCT THEREOF, AND ACYL PHOSPHINATE | ADEKA CORP (JP) | 2024-07-10 | — | — | EP | disclosed |
| CN-118103209-A | Composition for forming release layer, laminate, and method for producing laminate | 日产化学株式会社 | 2024-05-28 | — | — | CN | disclosed |
| US-11958802-B2 | Migration-resistant photopolymerization sensitizer | KAWASAKI KASEI CHEMICALS LTD. (JP) | 2024-04-16 | — | — | US | disclosed |
| CN-114616254-B | Acylphosphine composition, polymerization initiator, polymerizable composition, cured product, and method for producing same | 株式会社ADEKA | 2024-03-15 | — | — | CN | disclosed |
| CN-113166554-B | xanthene compounds | 株式会社艾迪科 | 2023-12-12 | — | — | CN | disclosed |
| WO-2023199738-A1 | COMPOSITION AND CURED PRODUCT | 株式会社ADEKA | 2023-10-19 | — | — | WO | disclosed |
| CN-113166036-B | Photopolymerizing sensitizers with migration resistance | 川崎化成工业株式会社 | 2023-10-10 | — | — | CN | disclosed |
| CN-110036343-B | Water-soluble composition, pattern forming agent, method for producing cured product using same, and cured product | 株式会社ADEKA | 2023-06-13 | — | — | CN | disclosed |
| US-11649334-B2 | Water-soluble composition, production method for cured product thereof, and cured product thereof, and acyl phosphinate | ADEKA CORPORATION (JP) | 2023-05-16 | — | — | US | disclosed |
| WO-2023074171-A1 | RELEASE LAYER-FORMING COMPOSITION, LAMINATE, AND METHOD FOR MANUFACTURING LAMINATE | 日産化学株式会社 | 2023-05-04 | — | — | WO | disclosed |
| WO-2010142779-A1 | ANTIFUNGAL 1,2,4-TRIAZOLYL DERIVATIVES HAVING A 5- SULFUR SUBSTITUENT | BASF SE (DE) | 2010-12-16 | — | — | WO | disclosed |
| EP-0893442-B1 | LYMPH-ABSORBABLE IMIDAZOLE DERIVATIVES | SHIONOGI & CO (JP) | 2005-01-12 | — | — | EP | disclosed |
| EP-0786455-B1 | IMIDAZOLE DERIVATIVE | SHIONOGI & CO (JP) | 2003-12-03 | — | — | EP | disclosed |
| US-6147097-A | METHOD FOR TREATING AIDS | SHIONOGI & CO., LTD. (JP) | 2000-11-14 | — | — | US | disclosed |
| US-6140338-A | FOR TREATING ACUTE INFLAMMATORY DISEASES, CHRONIC INFLAMMATORY DISEASES, ACQUIRED IMMUNE DEFICIENCY SYNDROME, CANCER, ISCHEMIC REFLOW DISORDER AND/OR ARTERIOSCLEROSIS | BANYU PHARMACEUTICAL, CO., LTD. (JP) | 2000-10-31 | — | — | US | disclosed |
| US-6054591-A | LYMPHOTROPIC ANTI-AIDS AGENT | SHIONOGI & CO., LTD. (JP) | 2000-04-25 | — | — | US | disclosed |
| US-5910506-A | IMIDAZOLE DERIVATIVES, E.G.5-(3,5-DICHLOROPHENYLTHIO)-1,2-DIMETHYL-4-ISOPROPYL-1H-IMIDAZOLE; VIRICIDES; AIDS; NONTOXIC | SHIONOGI & CO., LTD. (JP) | 1999-06-08 | — | — | US | disclosed |
| EP-0916668-A1 | CHEMOKINE RECEPTOR ANTAGONISTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1999-05-19 | — | — | EP | disclosed |
| EP-0893442-A1 | LYMPH-ABSORBABLE IMIDAZOLE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 1999-01-27 | — | — | EP | disclosed |
| EP-0786455-A1 | IMIDAZOLE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 1997-07-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11958802-B2 | Migration-resistant photopolymerization sensitizer | F12, F10, PCNA | CYP1A2 356/4885SIGMAR1 2719/4885HPGD 756/4885 |
| US-11649334-B2 | Water-soluble composition, production method for cured product thereof, and cured product thereof, and acyl phosphinate | PHOSPHO1, ASS1, SGMS1 | CYP1A2 2508/4885SIGMAR1 2309/4885HPGD 1824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.